FY24 consensus $4.72. Raises FY24 revenue view to $594M-$602M from $540M-$560M, consensus $590.31M. Sees FY24 adjusted EBITDA $149M-$153M. Guidance includes Purified Cortrophin Gel net revenues of $196M-$200M, representing year-over-year growth of 75%-78%, and ILUVIEN and YUTIQ net revenues of $30M-$32M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Ani Pharmaceuticals (ANIP) Q3 Earnings Cheat Sheet
- ANI Pharmaceuticals announces FDA approval of Estradiol Gel, 0.06%
- ANI Pharmaceuticals price target raised to $62 from $60 at Truist
- ANI Pharmaceuticals initiated with an Overweight at Piper Sandler
- ANI Pharmaceuticals announces FDA approval, launch of Ketoconazole Shampoo, 2%